Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 12Other hematologic neoplasm 8Gastrointestinal 8Dermatologic 5Lymphoid 2CNS 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Neoplasm of Uncertain Malignant Potential 1

Interventions

Cisplatin 147pembrolizumab 129Carboplatin 126Injections 108Pemetrexed 99Paclitaxel 97Gemcitabine 85Irinotecan 75Cyclophosphamide 72Nivolumab 71Docetaxel 68Bevacizumab 59Oxaliplatin 50Fluorouracil 50Capecitabine 48atezolizumab 46Leucovorin 42Etoposide 42tislelizumab 40toripalimab 36fludarabine 32Drug Therapy 32Ipilimumab 30Topotecan 29durvalumab 28Vincristine 27Specimen Handling 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
peginterferon alfa-2a × Other solid neoplasm × Clear all
NCT00253474 2012-03-29

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
36 enrolled
Other solid neoplasm

Neoplasm of Uncertain Malignant Potential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡